EGFR and non-small cell lung carcinoma: Up to 40% of NSCLC patients with EGFR mutation develop central nervous system (CNS) metastases on or after first- or second-generation EGFR-TKIs treatment due to their poor penetration of the blood–brain barrier (BBB).